Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 1
1997 1
2003 3
2004 2
2005 2
2006 3
2007 2
2008 3
2009 2
2010 3
2011 8
2012 4
2013 2
2014 4
2015 7
2016 4
2017 6
2018 14
2019 20
2020 27
2021 33
2022 24
2023 14
2024 14
2025 9
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

185 results

Results by year

Filters applied: . Clear all
Page 1
The authors reply.
Hamano H, Chuma M, Takechi K, Ikeda Y. Hamano H, et al. Among authors: chuma m. Kidney Int. 2021 Apr;99(4):1026. doi: 10.1016/j.kint.2021.01.009. Kidney Int. 2021. PMID: 33745535 Free article. No abstract available.
Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data.
Zamami Y, Niimura T, Kawashiri T, Goda M, Naito Y, Fukushima K, Ushio S, Aizawa F, Hamano H, Okada N, Yagi K, Miyata K, Takechi K, Chuma M, Koyama T, Kobayashi D, Shimazoe T, Fujino H, Izawa-Ishizawa Y, Ishizawa K. Zamami Y, et al. Among authors: chuma m. Biomed Pharmacother. 2022 Apr;148:112744. doi: 10.1016/j.biopha.2022.112744. Epub 2022 Feb 28. Biomed Pharmacother. 2022. PMID: 35240525 Free article.
Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study.
Ji F, Tran S, Ogawa E, Huang CF, Suzuki T, Wong YJ, Toyoda H, Jun DW, Li L, Uojima H, Nozaki A, Chuma M, Tseng CH, Hsu YC, Ishigami M, Honda T, Atsukawa M, Haga H, Enomoto M, Trinh H, Preda CM, Vutien P, Landis C, Lee DH, Watanabe T, Takahashi H, Abe H, Asai A, Eguchi Y, Li J, Wang X, Li J, Liu J, Liang J, Lam CP, Huang R, Ye Q, Pan H, Zhang J, Cai D, Wang Q, Huang DQ, Wong G, Wong VW, Li J, Do S, Furusyo N, Nakamuta M, Nomura H, Kajiwara E, Yoon EL, Ahn SB, Azuma K, Dohmen K, An J, Song DS, Cho HC, Kawano A, Koyanagi T, Ooho A, Satoh T, Takahashi K, Yeh ML, Tsai PC, Yasuda S, Zhao Y, Liu Y, Okubo T, Itokawa N, Jun MJ, Ishikawa T, Takaguchi K, Senoh T, Zhang M, Zhao C, Alecu RI, Xuan Tay W, Devan P, Liu JK, Kozuka R, Vargas-Accarino E, Do AT, Maeda M, Chuang WL, Huang JF, Dai CY, Cheung R, Buti M, Niu J, Xie W, Ren H, Lim SG, Wu C, Yuen MF, Shang J, Zhu Q, Ueno Y, Tanaka Y, Hayashi J, Yu ML, Nguyen MH. Ji F, et al. Among authors: chuma m. J Clin Transl Hepatol. 2024 Jul 28;12(7):646-658. doi: 10.14218/JCTH.2024.00089. Epub 2024 Jun 17. J Clin Transl Hepatol. 2024. PMID: 38993510 Free PMC article.
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Ohara M, Suda G, Kohya R, Yasui Y, Tsuchiya K, Kurosaki M, Tani J, Maekawa S, Enomoto N, Chuma M, Morimoto M, Kaneko S, Nakagawa M, Asahina Y, Komori A, Kugiyama Y, Baba M, Nakamura A, Ito J, Yamada R, Hosoda S, Yamamoto Y, Yoshida S, Sho T, Sasaki T, Yoda T, Meno A, Yasuura N, Fu Q, Yang Z, Maehara O, Ohnishi S, Tokuchi Y, Kitagataya T, Kawagishi N, Nakai M, Ogawa K, Sakamoto N. Ohara M, et al. Among authors: chuma m. Hepatol Int. 2025 Dec;19(6):1371-1381. doi: 10.1007/s12072-025-10875-7. Epub 2025 Aug 28. Hepatol Int. 2025. PMID: 40875102
Research Ethics Consultation in Nursing Studies.
Kane C, Sakaguchi S, Chuma M, Yagi K, Takechi K, Aoe Y, Takagai T, Yanagawa H. Kane C, et al. Among authors: chuma m. J Empir Res Hum Res Ethics. 2022 Feb-Apr;17(1-2):63-69. doi: 10.1177/15562646211036577. Epub 2021 Aug 10. J Empir Res Hum Res Ethics. 2022. PMID: 34374568
Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis.
Chuma M, Nakamoto A, Bando T, Niimura T, Kondo Y, Hamano H, Okada N, Asada M, Zamami Y, Takechi K, Goda M, Miyata K, Yagi K, Yoshioka T, Izawa-Ishizawa Y, Yanagawa H, Tasaki Y, Ishizawa K. Chuma M, et al. Clin Infect Dis. 2022 Oct 12;75(8):1416-1422. doi: 10.1093/cid/ciac128. Clin Infect Dis. 2022. PMID: 35262686 Free PMC article.
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues.
Huang R, Jun DW, Toyoda H, Hsu YC, Trinh H, Nozaki A, Ishikawa T, Watanabe T, Uojima H, Huang DQ, Honda T, Tanaka Y, Vutien P, Marciano S, Abe H, Enomoto M, Atsukawa M, Takahashi H, Tsuji K, Takaguchi K, Tsai PC, Dai CY, Huang JF, Huang CF, Yeh ML, Yoon E, Kim SE, Ahn SB, Kim GA, Jung JH, Jeong SW, Oh H, Tseng CH, Ishigami M, Chau A, Maeda M, Yasuda S, Chuma M, Ito T, Kawashima K, Liu JK, Gadano A, Kozuka R, Itokawa N, Inoue K, Senoh T, Li J, Chuang WL, Cheung R, Wu C, Yu ML, Nguyen MH. Huang R, et al. Among authors: chuma m. Clin Mol Hepatol. 2025 Jul;31(3):1003-1017. doi: 10.3350/cmh.2024.1070. Epub 2025 Mar 17. Clin Mol Hepatol. 2025. PMID: 40091278 Free PMC article.
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.
Kohya R, Suda G, Ohara M, Hosoda S, Sho T, Chuma M, Komori A, Kugiyama Y, Yasui Y, Tsuchiya K, Kurosaki M, Tani J, Kaneko S, Nakagawa M, Asahina Y, Maekawa S, Enomoto N, Yamamoto Y, Baba M, Yamada R, Sasaki T, Yoda T, Yoshida S, Fu Q, Yang Z, Maehara O, Ohnishi S, Tokuchi Y, Kitagataya T, Kawagishi N, Nakai M, Natsuizaka M, Ogawa K, Sakamoto N. Kohya R, et al. Among authors: chuma m. JHEP Rep. 2025 Feb 19;7(5):101364. doi: 10.1016/j.jhepr.2025.101364. eCollection 2025 May. JHEP Rep. 2025. PMID: 40242310 Free PMC article.
Unveiling the association between fluoroquinolones and aortic diseases using real-world database analysis and pharmacological experiments.
Miyata K, Izawa-Ishizawa Y, Tsujinaka K, Nishi H, Itokazu S, Miyata T, Kondo M, Yoshioka T, Niimura T, Aizawa F, Yagi K, Sato M, Hyodo M, Hamano H, Kawada K, Chuma M, Zamami Y, Tsuneyama K, Goda M, Ishizawa K. Miyata K, et al. Among authors: chuma m. Biomed Pharmacother. 2024 Oct;179:117418. doi: 10.1016/j.biopha.2024.117418. Epub 2024 Sep 11. Biomed Pharmacother. 2024. PMID: 39265233 Free article.
Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma.
Chuma M, Uojima H, Toyoda H, Hiraoka A, Arase Y, Atsukawa M, Itokawa N, Okubo T, Tada T, Numata K, Morimoto M, Sugimori M, Nozaki A, Iwasaki S, Yasuda S, Koshiyama Y, Mishima Y, Tsuruya K, Tokoro C, Miura Y, Hidaka H, Kumada T, Kusano C, Kagawa T, Maeda S. Chuma M, et al. Hepatol Int. 2024 Oct;18(5):1472-1485. doi: 10.1007/s12072-024-10680-8. Epub 2024 Jul 4. Hepatol Int. 2024. PMID: 38963640
185 results